Mr. Dovey has been a Partner of Domain Associates, one of the largest medical only venture firms, since 1988. He has served on the board of 30+ companies financed by Domain. Previously he served as President of Rorer Group (now Sanofi Aventis as a result of subsequent mergers). During his tenure he was the primary architect of that Fortune 500 Company’s shift to pharmaceuticals that resulted in a doubling of annual sales to approximately $1 Billion. Before Rorer, he was President of Survival Technology - a start up medical products company, and he held management positions at Howmedica, Howmet Corporation, and New York Telephone. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. Mr. Dovey received his B.A. from Colgate University and his M.B.A. from Harvard Business School.
|
(see Management Biographies)
|
Dr. Hanson is Professor and Chairman of the Department of Biomedical Engineering, Oregon Health & Science University, Portland Oregon. Before assuming his present position in 2003 he was for 14 years a tenured Professor of Biomedical Engineering and Medicine at Emory University, Atlanta, GA. Dr. Hanson is inventor or co-inventor of 18 patents and has published over 200 scientific papers in areas of hemostasis, thrombosis and vascular biology. He holds a B.S. degree from the University of Pennsylvania, a M.S. degree from Stanford University, and a Ph.D. from the University of Washington, all in Chemical Engineering.
|
Dr. Hartmann is Head of the Patent Department Pharmaceuticals at Merck KGaA in Darmstadt, Germany and is also responsible for all patent affairs, including patent litigation of the Merck Group on a corporate level. During his 16 year career at Merck, he had been in the Licensing Department and the Business Development Unit until being promoted to his current position in 2000. Dr. Hartmann was a winner of the Merck Innovation Award in 2004 for his leadership in spinning projects out of Merck into startup venture capital backed companies. Dr. Hartmann holds a degree in Chemistry and a Ph. D. in Organic Chemistry from the University of Giessen.
|
Dr. Münchbach joined the Group in 2004 to launch and manage BB BIOTECH VENTURES II. Previously, he was Partner at BioMedinvest and Investment Advisor at HBM Partners. At BioMedinvest, he led several of the firm's investments, and served on the board of portfolio companies. Before the merger of HBM Bioventures and NMT New Medical Technologies, he was Investment Manager at NMT, where he was focusing on international private equity investments in biopharmaceutical and biotechnological companies. Before NMT, Dr. Münchbach gained experience in strategic marketing at Sanofi-Synthelabo. Dr. Münchbach holds a PhD in Protein Chemistry, a MSc in biochemistry and a Master in Economics from the Swiss Federal Institute of Technology (ETH), Zurich.
|
(see Management Biographies)
|
Eckard Weber, MD
Dr. Weber is a partner at Domain Associates where he creates companies around promising new pharmaceutical products. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including Cytovia, Acea, Novacea, NovaCardia, Novalar, Orexigen, Domain Antibacterial Acquisition Corporation, Ascenta, Ocera, Syndax, Tragara, Tobira, Sonexa and Calixa. He currently serves as interim CEO of Sonexa and Calixa, two seed-stage biopharmaceutical companies. He is Chairman of the Board at NovaCardia, Orexigen, Ocera, Ascenta, Tobira and Syndax. He was Chairman of Peninsula until it’s sale to Johnson & Johnson in 2005, Chairman of Cerexa until it’s sale to Forest Laboratories in January 2007, and a Board member of Conforma and Cabrellis until their sales to Biogen-IDEC and Pharmion, respectively. In addition, he is a board member of DiObex and BioVascular, Inc. Until 1995, Dr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific periodicals
|
